Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies

Hongshu Sui; Ningxia Ma; Ying Wang; Hui Li; Xiaoming Liu; Yanping Su; Jiali Yang

doi:10.1155/2018/6984948

Back

Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies

Journal article

Open access

Peer reviewed

Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies

Hongshu Sui, Ningxia Ma, Ying Wang, Hui Li, Xiaoming Liu, Yanping Su and Jiali Yang

Journal of immunology research, Vol.2018, pp.1-17

2018

DOI: 10.1155/2018/6984948

PMCID: PMC6109480

PMID: 30159341

Files and links (1)

url

https://doi.org/10.1155/2018/6984948View

Published (Version of record) Open Access

Abstract

Lung cancer remains a leading cause of cancer-related mortality worldwide with the poor prognosis. Encouragingly, immune checkpoint blockade targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) has dramatically changed the landscape for treatments in patients with non-small-cell lung cancer (NSCLC). However, only a small proportion of NSCLC patients responded to monotherapy of anti-PD-1/PDL1 agents; together, the development of resistance to anti-PD-1/PD-L1 therapy that leads to failure of anti-PD-1/PD-L1 therapy has significantly limited a broad applicability of the findings in clinical practices. Nowadays, several companion diagnostic assays for PDL1 expression have been introduced for identifying patients who may benefit the immunotherapy. In addition, results from clinical trials explored combinatory therapeutic strategies with conventional and/or targeted therapy reported a higher efficacy with an acceptable safety profile in NSCLC treatments, as compared to the monotherapy of these agents alone. In this review article, we summarized several anti-PD-1/PD-L1 agents licensed for NSCLC treatment, with a focus on predictive biomarkers and companion diagnostic assays for identification of NSCLC patients for immunotherapy anti-PD-1/PDL1 antibodies. Of a great interest, potentials of the combinatory therapy of anti-PD-1/PDL1 therapy with a conventional or targeted therapy, or other immunotherapy such as CAR-T cell therapy were emphasized in the article.

Genetic Engineering

Animals

Antibodies, Monoclonal - therapeutic use

B7-H1 Antigen - immunology

Carcinoma, Non-Small-Cell Lung - immunology

Carcinoma, Non-Small-Cell Lung - therapy

Combined Modality Therapy

Drug-Related Side Effects and Adverse Reactions

Humans

Immunotherapy - methods

Lung Neoplasms - immunology

Lung Neoplasms - therapy

Programmed Cell Death 1 Receptor - immunology

Receptors, Antigen, T-Cell - genetics

T-Cell Antigen Receptor Specificity

T-Lymphocytes - immunology

Details

Title: Subtitle: Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies
Creators: Hongshu Sui - Taishan Medical University
Ningxia Ma - Ningxia Medical University
Ying Wang - Ningxia Medical University
Hui Li - Ningxia Medical University
Xiaoming Liu - Ningxia Medical University
Yanping Su - Taishan Medical University
Jiali Yang - Ningxia Medical University
Resource Type: Journal article
Publication Details: Journal of immunology research, Vol.2018, pp.1-17
DOI: 10.1155/2018/6984948
PMID: 30159341
PMCID: PMC6109480
NLM abbreviation: J Immunol Res
ISSN: 2314-8861
eISSN: 2314-7156
Grant note: DOI: 10.13039/501100004179, name: Taishan Medical University, award: XY2017172, 81670004
Language: English
Date published: 2018
Academic Unit: Anatomy and Cell Biology
Record Identifier: 9984286263202771

Metrics

135 Record Views

162 Times Cited - Web of Science